(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
20 March 2008 (20.03.2008)

PCT

(10) International Publication Number
WO 2008/033105 A1

(51) International Patent Classification:
C12N 15/13 (2006.01) *A61K 39/42* (2006.01)
C07K 16/08 (2006.01) *A61P 31/16* (2006.01)

(21) International Application Number:
PCT/SG2007/000310

(22) International Filing Date:
13 September 2007 (13.09.2007)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
US60/844,246 13 September 2006 (13.09.2006) US

(71) Applicants *(for all designated States except US)*: **DSO NATIONAL LABORATORIES** [SG/SG]; 20 Science Park Drive, Singapore 118230 (SG). **ST JUDE CHILDREN'S RESEARCH HOSPITAL** [US/US]; Department of Infectious Disease, 332N Lauderdale, Memphis, TN 38105 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **HANSON, Brendon, J.** [AU/SG]; DSO National Laboratories, 20 Science Park Drive, Singapore 118230 (SG). **LIM, Angeline, P., C.** [SG/SG]; DSO National Laboratories, 20 Science Park Drive, Singapore 118230 (SG). **OOI, Eng Eong** [SG/SG]; DSO National Laboratories, 20 Science Park Drive, Singapore 118230 (SG). **BOON, Adrianus, C.M.** [US/US]; St Jude Children's Research Hospital, Department of Infectious Disease, 332N Lauderdale, Memphis, TN 38105 (US). **WEBBY, Richard, J.** [NZ/US]; St Jude Children'S Research Hospital, Department of Infectious Disease, 332 N Lauderdale, Memphis, TN 38105 (US).

(74) Agent: **YU SARN AUDREY & PARTNERS**; 190 Middle Road, #12-04, Singapore 188979 (SG).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*
— *of inventorship (Rule 4.17(iv))*

Published:
— *with international search report*
— *with sequence listing part of description published separately in electronic form and available upon request from the International Bureau*

(48) Date of publication of this corrected version:
8 May 2008

(15) Information about Correction:
see Notice of 8 May 2008

(54) Title: HEMAGGLUTININ ANTIBODY AND USES THEREOF

(57) Abstract: Passive antibody therapy as a tool for both prophylaxis against- and treatment of- highly pathogenic H5N1 influenza virus, providing immediate immunity is described. It is provided by an antibody specific to hemagglutinin capable of neutralizing influenza viruses and methods of making and using the same, the methods and compounds described herein may be used in diagnostic, prophylactic and therapeutic methods.

WO 2008/033105 A1